Retinopathy of Prematurity (ROP)
Vasoproliferative Retinal Disorder of Premature Infants
Primary risk age: Premature Neonates (Typically born <30 weeks gestation or birth weight <1500 grams)
- Urgency
- Severe
- Typical age
- Premature Neonates (Typically born <30 weeks gestation or birth weight <1500 grams)
- Body system
- Ophthalmological System
Typical course: Retinal vascularization completes around 40 to 45 weeks post-menstrual age; follow-up is maintained for years.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Vasoproliferative Retinal Disorder of Premature Infants
Pathophysiology (Development Path)
Retinal vessels grow from the center outward, completing development near birth. In a premature infant, growth is incomplete. Hyperoxia down-regulates Vascular Endothelial Growth Factor (VEGF), halting vessel growth. As the retina matures, it becomes hypoxic, triggering a massive, unregulated release of VEGF. This drives abnormal, fragile blood vessel growth (neovascularization) that leaks and pulls on the retina.
Primary Causes & Etiology
Incomplete retinal vascularization at birth, combined with exposure to high, unregulated oxygen concentrations (hyperoxia) and fluctuating oxygen levels.
2. Symptom Continuum
- Early Onset Signs
Visually normal externally. ROP is asymptomatic in its early stages and can only be detected via dilated ophthalmoscopic screening.
- Progressive Phase
Development of a white line (demarcation) separating vascularized and avascular retina, progressing to a ridge of tissue and neovascularization extending into the vitreous (Stages 1-3).
- Severe Indicators
Subtotal or total retinal detachment (Stages 4-5) due to traction from scar tissue, resulting in leukocoria (white pupillary reflex), strabismus, and severe, irreversible blindness.
3. Clinical Verification
Serial dilated retinal examinations performed by a pediatric ophthalmologist in the NICU, beginning at 4 weeks of life or 31 weeks post-menstrual age.
4. Care & Elements Plan
Primary Care Treatment Plan
Carefully regulate neonatal oxygen delivery (maintain SpO2 targets between 91-95%). For severe ROP, apply laser photocoagulation to the avascular retina, or administer intravitreal injections of anti-VEGF agents.
Home Support Elements
Ensure absolute compliance with all follow-up ophthalmology appointments after discharge from the NICU. Monitor for any signs of visual preference or abnormal eye movements.
Generic Active Ingredients (No Brands)
- Ranibizumab or Bevacizumab (generic active monoclonal anti-VEGF antibodies used for intravitreal injection in severe cases).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Any premature infant meeting screening criteria must undergo scheduled ophthalmological evaluation; seek immediate care for a white pupillary reflex or lack of eye contact.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
Avoid excessive, unregulated oxygen delivery in the NICU. Maintain stable oxygenation parameters and prevent maternal premature birth.
Immunization Context
No specific immunizations are associated with this developmental vascular disease.
7. Timelines & Outlook
Active Timeline
Retinal vascularization completes around 40 to 45 weeks post-menstrual age; follow-up is maintained for years.
Expected Prognosis
Excellent with early detection and modern therapies; over 90% of infants with early-stage ROP recover completely without treatment or visual loss.
Potential Untreated Complications
Retinal detachment, severe myopia, strabismus, amblyopia, glaucoma, and permanent blindness.
